GRAIL loses $2.2B in market cap as class action follows trial failure

GRAIL Inc. shed more than $2.2 billion in market capitalization on Feb. 20 after its NHS-Galleri cancer screening trial failed to meet its primary endpoint, triggering a securities class action lawsuit.

"The complaint alleges that GRAIL misled investors by creating the false impression that it possessed reliable information supportive of the probability of the trial achieving its primary endpoint," Reed Kathrein, partner at Hagens Berman leading the firm's investigation, said.

The trial enrolled 140,000 participants and aimed to show a statistically significant reduction in combined Stage III and IV cancer diagnoses over three consecutive years of follow-up screening. GRAIL disclosed on Feb. 19 that the primary endpoint "was not observed," with management acknowledging "we probably should have allowed for a longer follow-up period." Shares collapsed 50.55 percent, falling from $101.53 to $50.21 and erasing $51.32 per share in value.

The class action seeks to represent investors who purchased GRAIL common stock between May 13, 2025 and Feb. 19, 2026. During that period, GRAIL expressed high confidence in the trial design and repeatedly characterized early results as "very encouraging" while declining to share detailed data, citing trial integrity. The lead plaintiff deadline is Aug. 4, 2026. A separate suit was filed by Levi & Korsinsky on behalf of shareholders. The trial failure undermines GRAIL's core value proposition in multi-cancer early detection and raises questions about the Galleri test's path to broader adoption. Investors will watch for any updates on a potential trial redesign or regulatory engagement in coming quarters.

This article is for informational purposes only and does not constitute investment advice.